The EuroBiotech Journal (Oct 2017)

Genetic testing for Bardet-Biedl syndrome

  • Abeshi Andi,
  • Fanelli Francesca,
  • Beccari Tommaso,
  • Dundar Munis,
  • D’Esposito Fabiana,
  • Bertelli Matteo

DOI
https://doi.org/10.24190/ISSN2564-615X/2017/S1.04
Journal volume & issue
Vol. 1, no. s1
pp. 14 – 16

Abstract

Read online

We studied the scientific literature and disease guidelines in order to summarize the clinical utility of genetic testing for Bardet- Biedl syndrome (BBS). The disease has autosomal recessive inheritance, a prevalence varying from one in 13 500 to one in 160 000, and is caused by mutations in the ARL6, BBIP1, BBS1, BBS2, BBS4, BBS5, BBS7, BBS9, BBS10, BBS12, CEP290, IFT172, IFT27, LZTFL1, MKKS, MKS1, NPHP1, SDCCAG8, TRIM32, TTC8 and WDPCP genes. The clinical diagnosis of BBS is based on four primary features or three primary features plus two secondary features. The genetic test is useful for confirming diagnosis, and for differential diagnosis, couple risk assessment and access to clinical trials.